Français
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
10 résultats
R-(-)-Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose of R-(-)-gossypol acetic acid (AT-101) that can be combined with lenalidomide and dexamethasone in patients with relapsed symptomatic multiple myeloma (MM). (Phase I) II. To determine the overall response rate (partial response or
Gossypol Combined With Docetaxel and Cisplatin Scheme in Advanced Non Small-cell Lung Cancers With APE1 High Expression
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose (MTD) of lenalidomide in combination with AT-101 (R-(-)-gossypol acetic acid). (Phase I) II. To assess the overall response rate of lenalidomide in combination with AT-101. (Phase II)
SECONDARY OBJECTIVES:
I. To assess the overall
Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
PRIMARY OBJECTIVES:
I. The primary end point will be to determine the maximum tolerated dose of AT-101 with paclitaxel and carboplatin.
SECONDARY OBJECTIVES:
I. To describe the toxicities associated with the combination of paclitaxel, carboplatin, and AT-101.
II. To evaluate the human
Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
PRIMARY OBJECTIVE:
I. To determine the proportion of patients with recurrent, metastatic, or primary unresectable adrenocortical carcinoma who achieve an objective response to R-(-)-gossypol acetic acid.
SECONDARY OBJECTIVES::
I. To evaluate the safety of this drug in these patients. II. To
R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
PRIMARY OBJECTIVES:
I. To determine the objective response rate of R-(-)-gossypol in patients with recurrent chemotherapy-sensitive extensive stage small cell lung cancer.
II. To determine the time to disease progression. III. To determine the overall survival. IV. To assess the toxicities
R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
PRIMARY OBJECTIVE:
I. To determine the percentage of patients with newly diagnosed metastatic prostate cancer who demonstrate undetectable prostate-specific antigen (PSA) (< 0.2 ng/mL) at 7 months when treated with R-(-)-gossypol (AT-101) and androgen ablation therapy.
SECONDARY OBJECTIVES:
I. To
R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) of AT-101 (R-(-)-gossypol) when combined with cisplatin and etoposide in patients with advanced, refractory solid tumors and/or extensive stage small cell lung cancer (ES-SCLC). In addition, to
Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
PRIMARY OBJECTIVES:
I. To estimate the overall survival rate associated with AT-101 in treating adult patients with recurrent glioblastoma multiforme.
SECONDARY OBJECTIVES:
I. To assess and estimate the acute and late toxicities. II. Tumor response rate. III. To estimate 6-month progression free
Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
OBJECTIVES:
Primary
- Determine the maximum tolerated dose (MTD) of gossypol (AT-101) when administered with radiotherapy (RT) and concurrent temozolomide (TMZ) in patients with newly diagnosed glioblastoma multiforme.
- Determine the MTD of gossypol when administered with adjuvant TMZ after
La base de données d'herbes médicinales la plus complète soutenue par la science
- Fonctionne en 55 langues
- Cures à base de plantes soutenues par la science
- Reconnaissance des herbes par image
- Carte GPS interactive - étiquetez les herbes sur place (à venir)
- Lisez les publications scientifiques liées à votre recherche
- Rechercher les herbes médicinales par leurs effets
- Organisez vos intérêts et restez à jour avec les nouvelles recherches, essais cliniques et brevets
Tapez un symptôme ou une maladie et lisez des informations sur les herbes qui pourraient aider, tapez une herbe et voyez les maladies et symptômes contre lesquels elle est utilisée.
* Toutes les informations sont basées sur des recherches scientifiques publiées
